Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B | Alive

Total Raised


Last Raised

$19M | 1 yr ago


BiVACOR is a total artificial heart designed to take over the complete function of a patient's failing heart. The company's world headquarters is located in Houston, Texas, USA, and its international office is in Brisbane, Australia.

BiVACOR Headquarters Location

2450 Holcombe Boulevard Ste. X+

Houston, Texas, 77021,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BiVACOR

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BiVACOR is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,490 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

BiVACOR Patents

BiVACOR has filed 8 patents.

The 3 most popular patent topics include:

  • Fluid dynamics
  • Pumps
  • Cardiology
patents chart

Application Date

Grant Date


Related Topics




Fluid dynamics, Pumps, Cardiology, Implants (medicine), Fluid mechanics


Application Date


Grant Date



Related Topics

Fluid dynamics, Pumps, Cardiology, Implants (medicine), Fluid mechanics



Latest BiVACOR News

Ventricular Assist Device Global Market Report 2022

Sep 22, 2022

Major players in the ventricular assist device market are Berlin Heart GmbH, Abiomed Inc, ReliantHeart Inc, CorWave SA, Cirtec, Abbott, Cardiac Assist Inc, Jarvik Heart Inc, Bivacor Inc, Calon Cardio, Terumo Medical Corporation, Syncardia Systems LLC, Boston Scientific Corporation, Heart Ware International, and LivaNova PLC. September 22, 2022 11:08 ET Lyon, FRANCE New York, Sept. 22, 2022 (GLOBE NEWSWIRE) -- announces the release of the report "Ventricular Assist Device Global Market Report 2022" - The global ventricular assist device market is expected to grow from $1.51 billion in 2021 to $1.70 billion in 2022 at a compound annual growth rate (CAGR) of 13.01%. The ventricular assist device market is expected to reach $2.69 billion in 2026 at a CAGR of 12.16%. The ventricular assist device market consists of sales of ventricular assist devices by entities (organizations, sole traders, and partnerships) that refer to an implantable mechanical circulatory device used to treat heart failure by pumping blood from the heart to the rest of the body, improving circulation to vital organs. A wide range of ventricular assist devices are approved by the US FDA to provide long-term or permanent support to patients with end-stage heart failure. The main types of ventricular assist devices include left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs).The left ventricular assist devices refer to a battery-operated mechanical pump that helps in pumping blood from the left ventricle to the vital organs of the body. They are differentiated based on design into transcutaneous ventricular assist devices and implantable ventricular assist devices, and they operate on different flows which include pulsatile flow and continuous flow. they are used in hospitals, ambulatory surgical centers, and cardiology centers for bridge-transplant therapy, destination therapy, bridge-to-recovery therapy, and bridge-to-candidacy therapy. North America was the largest region in the ventricular assist device market in 2021.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ventricular assist device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The ventricular assist device market research report is one of a series of new reports that provides ventricular assist device market statistics, including ventricular assist device industry global market size, regional shares, competitors with a ventricular assist device market share, detailed ventricular assist device market segments, market trends and opportunities, and any further data you may need to thrive in the ventricular assist device industry. This ventricular assist device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The increase in the prevalence of cardiovascular disorders is driving the growth of the ventricular assist device market.Cardiovascular disorders are heart diseases caused by high blood pressure, smoking, high cholesterol, inactivity, and other factors. The increase in the prevalence of cardiovascular disorders is also due to noncontagious diseases such as diabetes, chronic respiratory illness, and heart attacks due to hypertension.The significant increase in cardiovascular disorders is expected to boost demand for ventricular assist devices as they act as a vital support system for severely ill cardiac patients. For instance, according to the World Health Organization (WHO), in 2019, 17.9 million people died from cardiovascular diseases accounting for 32% of all global deaths. Of these, 85% of deaths were due to stroke and heart attack. Therefore, the increase in the prevalence of cardiovascular disorders is expected to boost demand for ventricular assist devices during the forecast period. The rise in awareness regarding heart failure treatment is driving the growth of the ventricular assist device market.Heart failure is a disorder or set of symptoms that cause the heart to weaken or harden. Heart failure is defined by the heart’s inability to provide enough blood to the body, and coronary artery disease, heart attack, high blood pressure, and damage to the heart muscle are some causes of heart failure.The rapid rise in awareness regarding heart failure treatments is expected to boost the utilization of ventricular assist devices to treat heart failure. For instance, according to the digital health service company VPG Medical Inc, around 670,000 people are diagnosed with heart failure each year in the USA. Additionally, according to the study published by the Heart Failure Society of America (HFSA), the occurrence of heart failure is expected to rise from 6.5 million Americans to more than 8 million by 2030. Thus, the rise in awareness regarding heart failure treatment will drive the growth of the ventricular assist device market. Technological advancement is a key trend gaining popularity in the ventricular assist device market.The company operating in the ventricular assist device sector are focusing on developing next-generation ventricular assist devices to improve the function of blood circulation. Key players are focusing on developing ventricular assist devices with new technology to gain a competitive edge and strengthen their position in the market.For instance, CorWave, a France-based medical technology company has developed left ventricular assist device (LVAD) membrane pump technology. This LVAD based on membrane pump technology utilizes a pulse pump (electromagnetic pulses) instead of a rotary pump to move blood and more closely encourages the movement of blood in a heart. It creates a pulsatile pumping action much more similar to the native heart. The countries covered in the ventricular assist device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

BiVACOR Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo


  • When was BiVACOR founded?

    BiVACOR was founded in 2008.

  • Where is BiVACOR's headquarters?

    BiVACOR's headquarters is located at 2450 Holcombe Boulevard, Houston.

  • What is BiVACOR's latest funding round?

    BiVACOR's latest funding round is Series B.

  • How much did BiVACOR raise?

    BiVACOR raised a total of $22M.

  • Who are the investors of BiVACOR?

    Investors of BiVACOR include OneVentures, Cormorant Asset Management and National Institutes of Health.

  • Who are BiVACOR's competitors?

    Competitors of BiVACOR include Abiomed.

You May Also Like

Jarvik Heart

Jarvik Heart is a private company that develops miniaturized heart assist devices for the treatment of severe heart failure.

Teleflex Logo

Teleflex (NYSE: TFX) manufactures and markets surgical instruments and devices in the United States and internationally. It offers surgical instruments, appliances, cardiac devices, and other products. Teleflex was formerly known as Hudson Respiratory Care. The company was founded in 1943 and is based in Wayne, Pennsylvania.


ReliantHeart is a provider in mechanical circulatory support therapies for advanced stage heart failure. The company manufactures the HeartAssist5, a next generation ventricular assist device (VAD) which has CE Mark approval for commercial sale in Europe. The HeartAssist5 is an implantable, electric pump designed for use in patients requiring ventricular support due to end stage heart failure and is the world's only remotely monitored VAD.


Thoratec specializes in therapies to address advanced-stage heart failure. The company's products include the HeartMate II and HeartMate III LVAS (Left Ventricular Assist Systems) and Thoratec VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag and PediMag/PediVAS product lines. Thoratec is headquartered in Pleasanton, California.

SynCardia Systems

SynCardia Systems is a manufacturer of the Total Artificial Heart. The SynCardia Total Artificial Heart is approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers.On September 30th, 2021, SynCardia Systems was acquired by Picard Medical. The terms of the transaction were not disclosed.


Cardiac Assist, dba TandemLife, is a medical device company. It had developed the Tandemheart Transseptal Cannula- Ef 72.The TandemHeart PTVA System delivers true left ventricular support of up to 5. lpm, in minutes, not hours. A simple percutaneous approach that allows rapid implementation of circulatory support in the Cardiac Catheterization Laboratory or the Operating Room.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.